Takeda Pharmaceuticals Korea is approved for its crohn’s disease treatment, ‘Kinteles Inj.’ from the Ministry of Health and Welfare
Takeda Pharmaceuticals Korea (President Choon-yup Lee) announced that it has acquired an approval for its ulcerative colitis(UC) and crohn’s disease(CD) treatment, Kinteles Inj. (generic name: vedolizumab), from the Ministry of Food and Drug Safety.
Kinteles Inj., a treatment for adults with mod...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
